A securities fraud class action lawsuit has been filed against Erasca, Inc. on behalf of investors who purchased securities during the period of January 14, 2925 through April 26, 2026. The lawsuit alleges that Erasca and its top executives made false and misleading statements about its lead oncology drug candidate, ERAS-0015, presenting it as a potential best-in-class therapy with superior preclinical results compared to Revolution Medicines' competing drug RMC-6236, while failing to disclose that those comparisons were allegedly improper and lacked a reasonable basis. On April 27, 2026, Erasca disclosed a letter from RevMed alleging patent infringement and trade secret misappropriation, and separately reported preliminary Phase 1 data for ERAS-0015 that included a patient death and acknowledged that cross-study comparisons are inherently limited. Following these disclosures, Erasca's share price fell sharply, first by 11% and then by an additional 48% over two trading days. Investors have until August 10, 2026 to seek lead plaintiff appointment through Kirby McInerney LLP.
Erasca IncSecurities fraud lawsuit alleging false statements about ERAS-0015, plus patent infringement claims and adverse trial data.
Revolution Medicines IncRevMed's drug RMC-6236 is the comparator; Erasca's alleged improper comparisons and patent infringement claims against RevMed may strengthen RevMed's competitive position.